Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
Authors
Keywords
Hepatocellular carcinoma, Liver cancer, Immunotherapy, Immune checkpoint inhibitors, Anti-PD-1, Anti-CTLA-4, DC/CIK therapy
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 101, Issue -, Pages 108322
Publisher
Elsevier BV
Online
2021-11-01
DOI
10.1016/j.intimp.2021.108322
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
- (2021) Xiufeng Liu et al. Future Oncology
- Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
- (2021) Fausto Petrelli et al. Immunotherapy
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in molecular classification and precision oncology in hepatocellular carcinoma
- (2020) Sandra Rebouissou et al. JOURNAL OF HEPATOLOGY
- Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
- (2020) Daixi Ren et al. Molecular Cancer
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
- (2020) Bin Li et al. Frontiers in Immunology
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Efficacy of immune checkpoint inhibitors in different types of melanoma
- (2020) Ernesto Rossi et al. Human Vaccines & Immunotherapeutics
- Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
- (2020) Yung-Jue Bang et al. EUROPEAN JOURNAL OF CANCER
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- T-cell agonists in cancer immunotherapy
- (2020) Yeonjoo Choi et al. Journal for ImmunoTherapy of Cancer
- Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
- (2020) Nethanel Asher et al. Cancers
- Radiotherapy and Immunotherapy Combinations for Lung Cancer
- (2020) Vishesh Agrawal et al. Current Oncology Reports
- Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
- (2019) Charalampos S. Floudas et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in hepatocellular carcinoma
- (2019) Luigi Buonaguro et al. Annals of Hepatology
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab in cancer medicine: a comprehensive review
- (2019) Juliana Alvarez-Argote et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
- (2019) Alfredo Tartarone et al. Future Oncology
- Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
- (2019) Monireh Mohsenzadegan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
- (2019) Thomas Yau et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma: Mechanisms of progression and immunotherapy
- (2019) Yu Jiang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
- (2019) Giandomenico Roviello et al. Journal of Oncology
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
- (2019) M Lee et al. ANNALS OF ONCOLOGY
- LBA7Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
- (2019) C-H Hsu et al. ANNALS OF ONCOLOGY
- Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
- (2019) Andrew B. Nixon et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Immune checkpoint blockade therapy
- (2018) Thomas Wieder et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Dysfunction of antigen processing and presentation by dendritic cells in cancer
- (2018) Joanna Bandola-Simon et al. MOLECULAR IMMUNOLOGY
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
- (2018) Shishir Shetty et al. Nature Reviews Gastroenterology & Hepatology
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease
- (2018) Lei Dou et al. SEMINARS IN LIVER DISEASE
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies
- (2018) David Savitsky et al. CANCER RESEARCH
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
- (2018) Diana Llopiz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers
- (2018) Fabian Finkelmeier et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012
- (2017) Donna L. White et al. GASTROENTEROLOGY
- Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy
- (2017) Jingying Zhou et al. GUT
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
- (2017) Reem Waziry et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
- (2017) Vinay Prasad et al. SEMINARS IN ONCOLOGY
- Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma
- (2017) Jie Shen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma
- (2016) M. Simonelli et al. ANNALS OF ONCOLOGY
- Dendritic cell-based immunotherapy
- (2016) Rachel L Sabado et al. CELL RESEARCH
- Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
- (2016) K. F. Bol et al. CLINICAL CANCER RESEARCH
- Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
- (2016) Jessica L. Petrick et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- The use of pembrolizumab for the treatment of metastatic uveal melanoma
- (2016) Lisa A. Kottschade et al. MELANOMA RESEARCH
- Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2016) Safi Shahda et al. ONCOLOGIST
- Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
- (2016) Dong-Qiang Zeng et al. Oncotarget
- Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
- (2016) Li-Chun Lu et al. Liver Cancer
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
- (2015) Jeong-Hoon Lee et al. BRITISH JOURNAL OF CANCER
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
- (2015) Amit G. Singal et al. Clinical Gastroenterology and Hepatology
- Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma
- (2015) Mazen Noureddin et al. Clinics in Liver Disease
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
- (2015) Tim F Greten et al. GUT
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced toxicities and the gastroenterologist
- (2015) Robert Cheng et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
- (2015) George V. Papatheodoridis et al. JOURNAL OF HEPATOLOGY
- Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma
- (2015) Xiaojin Wang et al. JOURNAL OF SURGICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells
- (2015) Laura J Pallett et al. NATURE MEDICINE
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Hepatocellular Carcinoma: Diagnostic Performance of Multidetector CT and MR Imaging—A Systematic Review and Meta-Analysis
- (2015) Yoon Jin Lee et al. RADIOLOGY
- Pembrolizumab
- (2015) Leila Khoja et al. Journal for ImmunoTherapy of Cancer
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study
- (2013) C. Pocha et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach
- (2013) Abbas Mourad et al. HEPATOLOGY
- A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma
- (2013) Xiaozhou Yu et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
- (2013) Nancy E. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Immune surveillance by the liver
- (2013) Craig N Jenne et al. NATURE IMMUNOLOGY
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma
- (2013) Masato Abei et al. Radiation Oncology
- Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
- (2012) FUJIMASA TADA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells
- (2012) Antonella Carambia et al. JOURNAL OF HEPATOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma
- (2011) Pei Zhou et al. CANCER BIOLOGY & THERAPY
- Diagnostic Imaging and Biopsy Use Among Elderly Medicare Beneficiaries With Hepatocellular Carcinoma
- (2011) Nader N. Massarweh et al. Journal of Oncology Practice
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis
- (2009) A. SINGAL et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Mechanism of T cell tolerance induction by murine hepatic Kupffer cells
- (2008) Qiang You et al. HEPATOLOGY
- Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C
- (2008) Satoru Yatsuji et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started